Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
Reaction mass of 4,4'-[1,2-ethenediylbis[(3-sulfo-4,1-phenylene)imino[6-[bis(2-hydroxyethyl)amino]-1,3,5-triazine-4,2-diyl]imino]]bisarenoate sodium salt and 2-[[4-[bis(2-hydroxyethyl)amino]-6-[[4-[2-[4-[[4-[bis(2-hydroxyethyl)amino]-6-[arenoylamino]-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]ethenyl]-3-sulfophenyl]amino]-1,3,5-triazin-2-yl]amino]arenoate sodium salt and 2,2'-[1,2-ethenediylbis[(3-sulfo-4,1-phenylene)imino[6-[bis(2-hydroxyethyl)amino]-1,3,5-triazine-4,2-diyl]imino]]bisarenoate sodium salt
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Toxicity to reproduction
Administrative data
- Endpoint:
- two-generation reproductive toxicity
- Remarks:
- based on test type (migrated information)
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- GLP - Guideline study. According to the ECHA guidance document "Practical guide 6: How to report read-across and categories (March 2010)", the reliability was changed from RL1 to RL2 to reflect the fact that this study was conducted on a read-across substance.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 001
- Report date:
- 2001
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3800 (Reproduction and Fertility Effects)
- Deviations:
- no
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 416 (Two-Generation Reproduction Toxicity Study)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- MPI Research, Inc. 54943 North Main Street. Mattawan, MI 49071-9399
- Limit test:
- no
Test material
- Details on test material:
- - Name of test material (as cited in study report): C.I. Fluorescent Brightener 220
-Physical state: solid
- Analytical purity: 88.3%
- Lot/batch No.: DSR 9710004-006
- Stability under test conditions: September, 2001
- Storage condition of test material: room temperature, protect from light
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: CD (Crl:CD (SD)IGS BR) albino
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Portage, Michigan
- Age at study initiation: approx. 6 weeks
- Weight at study initiation: 52 to 78 g
- Fasting period before study: none
- Housing: individually in suspended, stainless steel, wire-mesh type cages except during mating where females were individually housed in plastic cages containing wood chip bedding
- Diet: certified meal Rodent chow #5002 from PMI Nutritionals International Inc. St. Louis, Missouri; ad libitum
- Water: tap water; ad libitum
- Acclimation period: 2-week
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18 - 24
- Humidity (%): 34 - 77
- Photoperiod (hrs dark / hrs light): 12/12
From: Jan. 17, 2000 To: Nov. 3, 2000
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
The required amount of test article was weighed and suspended in vehicle and mixed using a Polytron tissue homogenizer. The solutions were stirred with a magnetic stir bar, and then dispensed into amber glass containers using a syringe. Fresh suspensions were prepared for each dose group weekly, and stored refrigerated and protected from light for approximately 1 week.
- Maximal volume applied: 10 mL/kg bw
VEHICLE
- Concentration: 0.5%
- Lot/batch no. (if required): 108H0070 - Details on mating procedure:
- M/F ratio per cage: 1/1 (sequential, non-random matching; sibling matings avoided for F1 generation)
- Length of cohabitation: 14 days
- Proof of pregnancy: copulatory plug or sperm in vaginal smear referred to as day 0 of gestation
- After 14 days of unsuccessful pairing: non-pregnant females moved to plastic cages with woodchip bedding
- Further matings after two unsuccessful attempts: no
- After successful mating each pregnant female was caged individually (stainless steel, wire-mesh cages, then moved to plastic cages with woodchip bedding on gestational day 20). - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples were diluted with methanol and analyzed by HPLC (UV detection) for verification of concentration.
- Duration of treatment / exposure:
- Treatment of the parental (P) generation began 10 weeks prior to mating and continued until euthanasia. F1 and F2 generation offspring were potentially exposed in utero and during lactation. The F1 offspring selected to comprise the F1 parental group were exposed for ≥ 70 days prior to mating (beginning at age ≥ 28 days), until euthanasia.
- Frequency of treatment:
- once daily
- Details on study schedule:
- - F1 parental animals not mated until 11 weeks after selected from the F1 litters.
- Selection of parents from F1 generation when pups were 21 days of age.
- Age at mating of the mated animals in the study: 14 weeks
Doses / concentrations
- Remarks:
- Doses / Concentrations:
100, 300 and 1000 mg/kg bw/day
Basis:
actual ingested
- No. of animals per sex per dose:
- 26
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: selected by the sponsor on the basis of a range-finding study
Examinations
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: once weekly
BODY WEIGHT: Yes
- Time schedule for examinations: body weights recorded on day of arrival, prior to randomization, day 1 of dosing, and weekly during the study period. Mated females were weighed on days 0, 7, 14, and 20 of gestation, and rats that delivered litters were weighed on days 0, 4, 7, 14, and 21 of lactation. - Oestrous cyclicity (parental animals):
- Vaginal smears performed daily beginning 3 weeks prior to mating period in all P-generation females.
- Sperm parameters (parental animals):
- Sperm production, motility, and morphology performed following dissection
- Litter observations:
- STANDARDISATION OF LITTERS
- Performed on lactation day 4: maximum of 8 pups/litter (4/sex/litter as nearly as possible); excess pups were euthanized and necropsied
PARAMETERS EXAMINED
The following parameters were examined in F1 / F2 offspring: litter size, number of stillborn pups, number of live-born pups, gross pup abnormalities, and pup weight by sex
GROSS EXAMINATION OF DEAD PUPS: yes, any intact dead pups were necropsied - Postmortem examinations (parental animals):
- SACRIFICE
Performed on:
- P, F1, and F2 animals dying spontaneously or euthanized in extremis
- P and F1 females that showed evidence of mating but failed to deliver
- P and F1 females that showed no evidence of mating and failed to deliver
- P and F1 animals surviving to scheduled termination
- F1 and F2 pups culled on day 4 of lactation
- three F1 pups not chosen to continue on study per sex from each litter at weaning
- all F2 pups at weaning
GROSS NECROPSY
- Gross necropsy consisted of external and internal examinations.
HISTOPATHOLOGY / ORGAN WEIGHTS
The following organs and tissues were prepared for microscopic examination: brain, adrenal glands, epididymis, kidney, liver, pituitary gland, prostate, seminal vesicles with coagulating glands, spleen, testis, and ovaries. - Postmortem examinations (offspring):
- SACRIFICE
- The F1 offspring not selected as parental animals and all F2 offspring were sacrificed at 21 days of age were subjected to postmortem examinations macroscopic and microscopic examination
- intact pups dying during lactation were also subjected to postmortem examinations macroscopic and microscopic examination
GROSS NECROPSY
- Gross necropsy consisted of external and internal examinations - Statistics:
- The following parameters were analyzed statistically for significant differences: body weights, change in body weights, food consumption, fertility indices, reproductive organ weights, sperm parameters, follicle counts, number of uterine implantations, litter parameters (size, weight, and viability), and developmental indices.
- Reproductive indices:
- calculated
- Offspring viability indices:
- calculated
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- no effects observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- minor renal findings (dilatation pelvis, haemorrhage) at 1000 mg/kg bw (P and F1)
- Other effects:
- no effects observed
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- no effects observed
- Reproductive performance:
- no effects observed
Details on results (P0)
CLINICAL SIGNS AND MORTALITY
Free of observable abnormalities. 3 females died or were euthanized in extremis during the P generation: 2 in the 1000 mg/kg group and 1 in the 300 mg/kg group. It was concluded that the observed deaths were unlikely to be treatment-related.
ORGAN WEIGHTS
Treatment-related and significantly increased absolute and relative kidney weight (to brain and body weight) were observed in the 1000 mg/kg-group females when compared to control values. Similar changes were noted in F1 parents in the 1000 mg/kg group. Significant decreases in absolute and relative (to brain weight) epididymides weights were observed in the 300 and 1000 mg/kg groups compared to control values. As these decreases were not related to any microscopic epididymal changes or epididymal sperm counts, they were not considered to be treatment-related. Significant increases in absolute and relative (to brain weight) pituitary weight was observed in females in the 1000 mg/kg group compared to controls. As these increases were not related to any microscopic changes in the pituitary glands, they were not considered to be treatment-related.
F1 GENERATION:
CLINICAL SIGNS AND MORTALITY (PARENTAL ANIMALS)
Free of any observable abnormalities. 8 animals died or were euthanized in extremis during the study (2, 1, and 5 animals in the 100, 300, and 1000 mg/kg groups, respectively). As there were no abnormal clinical observations, and the number of deaths was comparable between treatment groups, these deaths were not considered to be treatment-related. Sporadic significant changes in body weight were observed in the treatment groups compared to the control. As no dose-related pattern was observed, these changes were not considered to be treatment-related.
FOOD CONSUMPTION:
A significant decrease in food consumption was noted in males in the 300 mg/kg group during the first 2 weeks of the premating period. As no dose-related pattern was observed, this decrease was not considered to be treatment-related.
ORGAN WEIGHTS
Significant increases in absolute and relative (to body weight) kidney weights were observed in males and females in the 1000 mg/kg group. Significantly increased relative kidney weight was observed in females in the 300 mg/kg group. Although a dose-related pattern was observed, these changes were not related to clear microscopic kidney changes; thus, the changes observed in the 1000 mg/kg group were not considered to be adverse. The changes observed in the 300 mg/kg group were considered to be spurious due to lack of change in total body weight, kidney weight relative to brain weight, and similar changes in male animals of the same dose group.
Significantly decreased absolute liver weights were observed in males in the 300 and 1000 mg/kg groups (compared to control values). Relative (to brain and body weights) liver weight was significantly decreased in males in the 300 mg/kg group. As there were no corresponding microscopic liver changes, these differences were not considered to be treatment-related.
Significant increases in absolute and relative adrenal gland weights were observed in females in the 1000 mg/kg group (compared to control values). As there were no corresponding microscopic adrenal gland changes, these differences were not considered to be treatment-related.
HISTOPATHOLOGY
One control male had epididymal aspermia and testicular atrophy, and 1 male in the 1000 mg/kg group had trace degeneration of the seminiferous tubules. These observations were not considered to be treatment-related.
Only minor renal findings were observed (mild dilatation pelvis) at 1000 mg/kg bw in 3 (F1) and in 1 (P) animals.
REPRODUCTIVE FUNCTION (ESTROUS CYCLES)
A significant increase in the number of estrous cycles was observed in the 300 mg/kg group. As no effect on estrous cycles was observed in the 1000 mg/kg group, this increase was not considered to be treatment-related.
Effect levels (P0)
open allclose all
- Dose descriptor:
- NOAEL
- Remarks:
- reproduction
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effects
- Dose descriptor:
- NOEL
- Remarks:
- toxicity
- Effect level:
- 300 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: increased kidney weight at 1000 mg/kg bw/day in females
- Dose descriptor:
- NOAEL
- Remarks:
- toxicity
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effects
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- no effects observed
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- not of biological relevance (< 10% difference from control)
- Sexual maturation:
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- not of biological relevance
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- not examined
Details on results (F1)
BODY WEIGHT
Significantly increased body weight (males and total pups) was observed for pups in the 1000 mg/kg group (compared to controls). This increase was not considered to be biologically meaningful as it was less than 10% difference from control values.
F2 GENERATION:
PARTURITION
A significant increase in the number of implant scars was observed in the 100 mg/kg group. As this increase was not observed in either of the higher dose groups, it was not considered to be treatment-related. A significantly higher sex ratio (% males) was noted in the 300 mg/kg group; however, this change was likely due to a lower % of male pups in the control group. Thus, this difference was not considered to be treatment-related.
BODY WEIGHT
Sporadic but significant increases in pup body weight were noted in all treatment group (versus control). Although these increases were considered to be treatment-related, they were not considered to be adverse.
ORGAN WEIGHTS
Significant increases in brain weight were observed in the 300 and 1000 mg/kg groups (compared to control). As these increases were considered to be the result of increased body weight, and were less than 10% different from control values, they were not considered to be biologically relevant or treatment-related.
Effect levels (F1)
open allclose all
- Dose descriptor:
- NOAEL
- Remarks:
- reproduction
- Generation:
- F1
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effects
- Dose descriptor:
- NOAEL
- Remarks:
- development
- Generation:
- F1
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effects
- Dose descriptor:
- NOEL
- Remarks:
- toxicity
- Generation:
- F1
- Effect level:
- 300 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: increased kidney weight at 1000 mg/kg bw/day
- Dose descriptor:
- NOAEL
- Remarks:
- toxicity
- Generation:
- F1
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effects
Results: F2 generation
Effect levels (F2)
- Dose descriptor:
- NOAEL
- Remarks:
- development
- Generation:
- F2
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effects
Overall reproductive toxicity
- Reproductive effects observed:
- not specified
Any other information on results incl. tables
Table 1: Summary of results – parental animals: P-generation
Parental animals (P) |
Dose group (mg/kg bw) |
||||
Parameter |
Sex |
0 (Vehicle control) |
100 |
300 |
1000 |
No. animals examined |
26 |
26 |
26 |
26 |
|
Macroscopic observation(no. animals affected) |
|||||
Kidney: dilated renal pelvis |
Male |
0 |
1 (mild) |
0 |
2 (1 mild, 1 moderate) |
|
Female |
0 |
0 |
1 (mild) |
0 |
Organ weights |
|||||
Epididymis (g) |
Male |
1.428 |
1.453 |
1.339* |
1.336* |
Kidney (g) |
Male |
4.275 |
4.214 |
4.212 |
4.425 |
Female |
2.542 |
2.486 |
2.692 |
2.768* |
|
Kidney/bw (%) |
Male |
0.739 |
0.719 |
0.760 |
0.774 |
Female |
0.827 |
0.797 |
0.845 |
0.887* |
|
Liver (g) |
Male |
20.818 |
20.323 |
19.519 |
20.180 |
Female |
12.356 |
12.667 |
13.064 |
12.953 |
|
Prostrate (g) |
Male |
0.898 |
0.872 |
8.843 |
0.820 |
Spleen (g) |
Male |
0.875 |
0.864 |
0.831 |
0.870 |
Female |
0.570 |
0.570 |
0.611 |
0.617 |
|
Testis (g) |
Male |
3.571 |
3.656 |
3.416 |
3.330 |
Ovary (g) |
Female |
0.127 |
0.130 |
0.134 |
0.141 |
Pituitary (g) |
Male |
0.013 |
0.013 |
0.014 |
0.013 |
Female |
0.015 |
0.0169 |
0.017 |
0.018* |
|
Pituitary/bw (%) |
Male |
0.002 |
0.002 |
0.002 |
0.002 |
Female |
0.005 |
0.005 |
0.005 |
0.006 |
|
Microscopical findings |
|||||
Kidney: |
Male |
0/10 |
0/3 |
0/4 |
1/14 |
-dilatation pelvis |
Male |
|
|
|
1 |
* Significantly different from control
Table 2: Summary of result – parental animals: F1-generation
F1-generation |
Dose group (mg/kg bw) |
||||
Parameter |
Sex |
0 (Vehicle control) |
100 |
300 |
1000 |
No. animals examined |
26 |
26 |
26 |
26 |
|
Macroscopic observation (no. animals affected) |
|||||
Kidney: |
Male |
2 |
2 |
3 |
5 |
-cyst |
1 |
0 |
0 |
0 |
|
-dilated renal pelvis |
1 |
2 |
3 |
5 |
|
-enlarged |
0 |
0 |
0 |
1 |
|
-white granular material |
0 |
0 |
1 |
0 |
|
Kidney: |
Female |
0 |
0 |
0 |
1 |
-dilated renal pelvis |
0 |
0 |
0 |
1 |
|
Organ weights |
|||||
Kidney (g) |
Male |
4.435 |
4.303 |
4.329 |
4.763* |
Female |
2.584 |
2.637 |
2.719 |
2.875* |
|
Kidney/bw (%) |
Male |
0.729 |
0.704 |
0.730 |
0.785* |
Female |
0.780 |
0.811 |
0.826* |
0.888* |
|
Liver (g) |
Male |
22.033 |
20.508 |
20.049* |
20.995* |
Female |
12.411 |
12.125 |
12.609 |
12.460 |
|
Liver/bw (%) |
Male |
3.606 |
3.351* |
3.368* |
3.449 |
Female |
3.738 |
3.732 |
3.831 |
3.852 |
|
Prostrate (g) |
Male |
1.139 |
1.142 |
1.117 |
1.102 |
Spleen (g) |
Male |
0.914 |
0.855 |
0.930 |
0.907 |
Female |
0.601 |
0.591 |
0.611 |
0.560 |
|
Testis (g) |
Male |
3.445 |
3.743 |
3.805* |
3.612 |
Testis/bw (%) |
Male |
0.568 |
0.613 |
0.649* |
0.595 |
Ovary (g) |
Female |
0.137 |
0.136 |
0.146 |
0.131 |
Pituitary (g) |
Male |
0.013 |
0.013 |
0.013 |
0.013 |
Female |
0.017 |
0.016 |
0.017 |
0.024 |
|
Pituitary/bw (%) |
Male |
0.002 |
0.002 |
0.002 |
0.002 |
Female |
0.005 |
0.005 |
0.005 |
0.008 |
|
Microscopical findings |
|||||
Kidney: |
Male |
0/14 |
0/5 |
0/5 |
2/15 |
-dilatation pelvis |
|
|
|
|
2 |
-haemorrhage |
|
|
|
|
1 |
Kidney: |
Female |
0/14 |
0/5 |
0/5 |
1/15 |
-dilatation pelvis |
|
|
|
|
1 |
Testis, degeneration, seminiferous tubules |
male |
0/14 |
0/5 |
0/5 |
1/15 |
* Significantly different from control
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Deși ECHA oferă o varietate bogată de materiale online în limba dumneavoastră, o parte din conţinutul acestei pagini este disponibil numai în limba engleză. Pentru mai multe informaţii referitoare la practica multilingvă a ECHA.
Bun venit pe site-ul ECHA. Acest site nu este deplin acceptat în Internet Explorer 7 (și versiuni anterioare). Vă rugăm să vă actualizați versiunea de Internet Explorer.
Acest site folosește module cookie pentru a garanta că aveți parte de cea mai bună experiență pe paginile noastre.
Aflați mai multe despre cum folosim modulele cookie.